FDA Approves NAYZILAM® to Treat Seizure Activity in People Living with Epilepsy

UCB announced the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for the company's newest anti-epileptic drug (AED) NAYZILAM® (midazolam) nasal spray CIV, a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. NAYZILAM now provides patients and caregivers with the first and only FDA-approved nasal option for treating seizure clusters.

It is estimated that more than 150,000 people in the U.S. with uncontrolled epilepsy also experience seizure clusters. Rescue treatment of seizure clusters is critical because when left untreated, seizure clusters can increase the risk of physical injury, neurological damage, prolonged seizures, and status epilepticus. Despite the impact of seizure clusters, many diagnosed patients may go untreated because currently available treatment options are not preferred.

NAYZILAM is a short-term treatment for seizure clusters in patients with epilepsy. The nasal spray is designed as a single-use treatment that can be carried with a patient. NAYZILAM allows for administration by a non-healthcare professional in patients actively seizing when and where a seizure cluster occurs. NAYZILAM can provide value to patients who are experiencing these disruptive seizures.

"As global leaders in epilepsy, the approval of NAYZILAM complements our already strong epilepsy portfolio, improving our ability to provide value to people living with poorly controlled seizures, and builds on our passion and expertise in this field. We are pleased to expand and diversify the solutions we can offer to the epilepsy community, providing an innovative and differentiated solution to help support management of seizure clusters," said Jean-Christophe Tellier, Chief Executive Officer, UCB.

NAYZILAM is the first new medication approved to treat seizure clusters in more than 20 years in the U.S.

"When a patient experiences seizure clusters, there is often significant impact on their overall quality of life, in addition to posing greater risks for increased emergency department related hospitalizations and more serious seizure emergencies," said Dr. Steven S. Chung, MD, Executive Director and Program Chair of the Neuroscience Institute and Director of the Epilepsy Program at Banner – University Medical Center. "Further, as a neurologist specializing in epilepsy, treating seizure clusters today presents a challenging barrier for many patients. The availability of a new treatment option, such as NAYZILAM, has potential to help improve the lives of patients and their families by providing another option for rescue care."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com.